Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K, Oriuchi N, Wakabayashi H, Tomiyama Y, Jinguji M, Higuchi T, Kayano D, Fukuoka M, Inaki A, Toratani A, Okamoto S, Shiga T, Ito YM, Nakajo M, Nakajo M, Kinuya S; Drafting Committee for Guidelines on Internal Radiotherapy with ¹³¹I-MIBG; Japanese Society of Nuclear Medicine in Oncology and Imunology; Japanese Society of Nuclear Medicine.
Yoshinaga K, et al. Among authors: nakajo m.
Endocr J. 2014;61(12):1171-80. doi: 10.1507/endocrj.EJ14-0211. Epub 2014 Sep 11.
Endocr J. 2014.
PMID: 25214026
Free article.